Drug Trial Radar · NCT03842969
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
236
Actual
Start
Apr 23, 2019
Primary completion
Mar 25, 2022
Study completion Mar 30, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042.
Conditions
- Huntington Disease
Interventions
RO7234292 (RG6042)Drug
Intrathecal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment Emergent Adverse EventsTime frame: Up to Approximately 3 Years
- Number of Participants With Suicidal Ideation, Suicidal Behavior, and Self-Injurious Behavior Without Suicidal Intent Based on the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to approximately 3 Years
- Change From Baseline in Cognition, Using Montreal Cognitive Assessment (MoCA)Time frame: Up to Approximately 3 Years
Locations
38 sites in 8 countries. Site status is shown where the registry gives one.
Uab Medicine
Birmingham, Alabama
University of California San Diego
La Jolla, California
Stanford Univ Medical Center
Palo Alto, California
SC3 Research Group, Inc
Pasadena, California
CenExel Rocky Mountain Clinical Research, LLC
Englewood, Colorado
Georgetown University; Research Division, Psychiatry
Washington D.C., District of Columbia
University of South Florida
Tampa, Florida
Northwestern University
Chicago, Illinois
John Hopkins University School of Medicine
Baltimore, Maryland
Dent Neurological Institute
Amherst, New York
Columbia University
New York, New York
University of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas Health Science Center at Houston; McGovern Medical School
Houston, Texas
Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie
Innsbruck, Austria
University of British Columbia Hospital; Division of Neurology
Vancouver, British Columbia, Canada
Centre for Movement Disorders
North YORK, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Centre Hospitalier de l?Université de Montréal (CHUM)
Montreal, Quebec, Canada
Charité - Universitätsmed. Berlin, Klinik für Psychiatrie und Psychotherapie; Abt. Neuropsychiatrie
Berlin, Germany
St. Josef-Hospital, Neurologische Klinik der Ruhr-Uni; Huntington-Center NRW, Abt. Neurodegeneration
Bochum, Germany
Universitätsklinikum Ulm; Klinik für Neurologie
Ulm, Germany
IRCCS Casa Sollievo Della Sofferenza; Unità Ricerca e Cura Huntington e Malattie Rare
San Giovanni Rotondo (FG), Apulia, Italy
Fondazione IRCCS Istituto Neurologico Carlo Besta; U.O.C. Genetica Medica-Neurogenetica
Milan, Lombardy, Italy
Universitair Medisch Centrum Groningen
Groningen, Netherlands
LUMC
Leiden, Netherlands
Hospital Universitario de Badajoz; Servicio de Neurología
Badajoz, Spain
Hospital Clinic Servicio de Neurologia
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia
Barcelona, Spain
Hospital Universitario de Burgos. Servicio de Neurología
Burgos, Spain
Hospital Ramon y Cajal; Servicio de Neurologia
Madrid, Spain
Fundacion Jimenez Diaz; Servicio de Neurología
Madrid, Spain
Hospital Universitario Virgen Macarena; Servicio de Neurologia
Seville, Spain
Birmingham and Solihull Mental Health Foundation Trust; Institute of Clinical Sciences
Birmingham, United Kingdom
Cambridge Centre for Brain Repair; Department of Clinical Nuerosciences, Addenbrookes Hospital
Cambridge, United Kingdom
University Hospital of Wales; Division of Psychological Medicine and Clinical Neurosciences
Cardiff, United Kingdom
University College London Hospitals NHS Foundation Trust - University College Hospital
London, United Kingdom
Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.